Hunan Nucien Pharmaceutical Co., Ltd.

The company focuses on R&D, production and marketing of chemical drugs, and is committed to the development and industrialization of new drugs and specific drugs for major diseases and sudden diseases to better meet clinical drug use needs and serve the “Healthy China” strategy. The company's product development is guided by innovative drug research and development. The products under development and existing product reserves have formed an orderly hierarchy, and have achieved a good layout in various series of products such as anti-influenza drugs, anti-tumor drugs, diabetic nephropathy drugs, cardiovascular drugs, and anti-infective drugs. The company focuses on R&D, production and sales of anti-viral and infectious disease prevention drugs such as influenza, as well as drugs to treat other major diseases such as malignant tumors, cardiovascular diseases, and diabetes. Main products: Paramivir sodium chloride injection, oseltamivir phosphate suspension, compound ibuprofen tablets, simvastatin dispersible tablets, atorvastatin calcium tablets, benazepril hydrochlorothiazide tablets, cefuroxime dispersible tablets, cefaclor capsules, cefaclor suspension, ciprofloxacin lactate sodium chloride injection, ibuprofen suspension drops, etc. Corporate honors: In 2020, the company insisted on innovation leading development, increased investment in R&D, further enriched research projects, made significant progress in R&D work on various projects, and won many honors such as “China Patent Silver Award”, “2019 China Pharmaceutical Industry Top 100 Series List”, and “2020 China Pharmaceutical Brand List”.